How effective is Paxlovid (nirmatrelvir/ritonavir) against the currently circulating Omicron sub‑variants of SARS‑CoV‑2?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Paxlovid Remains Highly Effective Against Current COVID-19 Strains

Paxlovid (nirmatrelvir/ritonavir) maintains robust antiviral activity against all currently circulating Omicron subvariants and should be used in high-risk patients with mild-to-moderate COVID-19 within 5 days of symptom onset. 1, 2

Evidence for Maintained Effectiveness

The FDA label confirms Paxlovid is indicated for treating mild-to-moderate COVID-19 in high-risk adults 2, and current guidelines from the American College of Physicians (2024) continue to support its use 1.

Virologic Activity Against Current Strains

Laboratory testing demonstrates that nirmatrelvir maintains potent antiviral activity against contemporary variants:

  • All 20 tested variants from 2020-2024 showed robust susceptibility, with only modest reductions in certain Beta variants 3
  • The SARS-CoV-2 main protease (Mpro) target remains completely conserved among current variants including JN.1, XEC, KP.3.1.1, NB.1.8.1, LP.8.1, XFG, and BA.3.2 3
  • Against Omicron subvariants BA.2 through XBB.1.5, nirmatrelvir showed median EC50 values with fold-changes ≤1.5 compared to the original strain 2
  • Testing of BQ.1.1, BF.7, BA.5.2, XBB.1, XBB.1.5, and BN.1.9 variants showed maximal IC50 fold-change of only 1.4, indicating preserved activity 4

Clinical Effectiveness Data

Real-world evidence from the Omicron era demonstrates substantial clinical benefit:

Mortality reduction: The most recent meta-analysis (2026) of 46 observational studies including over 6 million patients showed Paxlovid reduces:

  • All-cause mortality by 70% (RR 0.30,95% CI 0.23-0.39) 5
  • COVID-19 mortality by 57% (RR 0.43,95% CI 0.32-0.59) 5

Hospitalization reduction:

  • All-cause hospitalization reduced by 46% (RR 0.54,95% CI 0.43-0.68) 5
  • COVID-19hospitalization reduced by 55% (RR 0.45,95% CI 0.36-0.56) 5

Variant-specific effectiveness: Direct comparison studies during BQ.1/BQ.1.1/XBB.1.5 predominance showed non-inferior hospitalization rates compared to earlier Omicron phases (BA.2/BA.4/BA.5), with adjusted OR 0.76 (95% CI 0.54-1.06) 6. When compared to untreated contemporaneous patients, Paxlovid reduced 28-day hospitalization by 66% (aOR 0.34,95% CI 0.30-0.38) 6.

Who Benefits Most

The treatment effect varies significantly by immunity status:

  • Unvaccinated patients without prior infection: Greatest benefit with mortality reduction aRR 0.38 (95% CI 0.18-0.67) 7
  • Recently vaccinated patients: Smaller but still meaningful benefit with aRR 0.95 (95% CI 0.64-1.39) 7
  • Immunocompromised patients: Smaller mortality reduction (RR 0.26 vs 0.11 in immunocompetent; p=0.034) 5

Absolute Risk Reduction by Patient Risk Level

Using validated risk scores, the number needed to treat (NNT) to prevent one COVID-19 hospitalization is:

  • Low-risk patients (0.16% baseline risk): NNT = 1,148
  • Moderate-risk patients (2.2% baseline risk): NNT = 84
  • High-risk patients (8.9% baseline risk): NNT = 20 5

Critical Implementation Points

Timing is essential: Treatment must be initiated within 5 days of symptom onset 1, 2. The drug works by inhibiting viral replication, which is most active early in infection.

High-risk criteria include: Age ≥65, obesity, diabetes, chronic kidney disease, cardiovascular disease, chronic lung disease, immunosuppression, or other conditions increasing risk of severe COVID-19 2.

Common pitfall: The extensive drug-drug interactions with ritonavir require careful medication review. Nirmatrelvir is a potent CYP3A inhibitor that increases levels of midazolam by 1,430% and dabigatran by 194% 2. Review all concomitant medications before prescribing.

Bottom Line

The molecular target of Paxlovid (the SARS-CoV-2 main protease) remains unchanged across all current variants, and both laboratory and clinical data confirm maintained effectiveness. The benefit is most pronounced in unvaccinated or immunologically naive patients, but meaningful reductions in hospitalization and death persist even in vaccinated populations during the current Omicron era. Prioritize treatment for moderate-to-high risk patients where the NNT is clinically meaningful (84 and 20 respectively).

References

7
Research

The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2026

Related Questions

Is hydrocortisone safe to use during pregnancy?
In a patient with an estimated glomerular filtration rate of 53 mL/min/1.73 m², a urine protein‑creatinine ratio of 168 mg/g, blood pressure 129/80 mmHg, and not currently on an angiotensin‑converting enzyme inhibitor or angiotensin receptor blocker, can I initiate an ACE inhibitor or ARB?
For a United States paramedic, what are the pathophysiology, typical demographics, clinical signs, early and late EMS assessment findings, differential features, emergency medical services management—including airway, breathing, circulation, thiamine dosing, fluid and medication protocols—and complications of untreated Wernicke encephalopathy?
What is the optimal antibiotic regimen for a diabetic foot infection?
How long does analgesia last after a single epidural bolus of bupivacaine?
How does insecticide exposure increase the risk of respiratory inflammation and what is the recommended evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.